Research Article

Effect of Dexmedetomidine Low Doses with or without Midazolam in Cats: Clinical, Hemodynamic, Blood Gas Analysis, and Echocardiographic Effects

Marina Lopes Castro,1 Bruna Maia Cerqueira Câmera,1 Maira Souza Oliveira Barreto,2 Raphael Rocha Wenceslau,2 Andressa Karollini e Silva,1 Natália Fagundes,1 Renata Andrade Silva,1 Eutálio Luiz Mariani Pimenta,2 and Suzane Lilian Beier2

1Animal Science Post Graduation Program, Federal University of Minas Gerais, Department of Veterinary Medicine and Surgery, Belo Horizonte, Minas Gerais, Brazil
2Veterinary Internal Medicine and Surgery Department, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

Correspondence should be addressed to Marina Lopes Castro; marinalopes@vetufmg.edu.br

Received 6 June 2022; Accepted 29 August 2022; Published 24 November 2022

Academic Editor: Giuseppe Minervini

Copyright © 2022 Marina Lopes Castro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objectives. The aim of the study is to compare the sedative, cardiorespiratory, echocardiographic, and blood gas effects of dexmedetomidine and methadone associated or not with midazolam for restraint chemistry in cats.

Methods. Eighteen healthy young cats (4.06 ± 0.48 kg) were randomly sedated with two protocols, through the intramuscular route: dexmedetomidine (5 µg.kg⁻¹), methadone (0.3 mg.kg⁻¹) and midazolam (0.3 mg.kg⁻¹) (DMTM, n = 9), or dexmedetomidine (7.5 µg.kg⁻¹) and methadone (0.3 mg.kg⁻¹) (DMT, n = 9). The cardiorespiratory parameters were measured at baseline, 5 and 10 minutes after pharmacological latency. The sedation, analgesia, and muscle relaxation scores were assessed before and 5 minutes after pharmacological latency, while arterial blood gas analysis and echocardiography were assessed before and after 10 or 15 minutes, respectively.

Results. There was no difference between the protocols regarding the cardiorespiratory, blood gas, and echocardiographic parameters used. The scores for sedation, analgesia, and muscle relaxation also did not differ between the protocols, with the degree of sedation, analgesia, and myorelaxation considered satisfactory in both groups. A significant decrease in heart rate (HR) was observed after administration of the sedative protocols, reaching a maximum reduction at T10 (46% and 53% reduction in the DMT and DMTM groups, respectively). The reduction in HR had an impact on echocardiographic parameters such as CO, which decreased 53% and 56% in the DMT and DMTM groups, respectively. There was a significant reduction in PaO₂, SaO₂, ejection fraction, and fractional shortening in both protocols. SpO₂ decreased significantly after 5 minutes of sedation in the DMT group, but with a minimum mean SpO₂ of 92% in T5. The respiratory rate decreased significantly at 5 and 10 minutes in the DMTM group, while PaCO₂ increased in both groups, indicating respiratory depression caused by the drugs.

Conclusions and Relevance. The study pointed out that both sedative protocols can be recommended for clinical sedation of young and healthy cats in the doses used. However, both protocols resulted in cardiorespiratory depression in cats and also the particularities of the animals should be evaluated regarding reducing cardiac output by more than 50%.

1. Introduction

The physiological and morphological particularities of felines differ from the canine species mainly because these animals are less tolerant to handling and physical restraint [1–4].

Sedation in cats is often required for diagnostic procedures such as echocardiographic examination. The aim of sedation is lower stress, fear, and anxiety and also provide relaxation and when necessary, analgesia. [5] Furthermore, morbidity and mortality during anesthesia in this species are considerably higher as compared to dogs [6].
The use of α2-adrenergic receptor agonists brings benefits to clinical anaesthesiology, especially dexmedetomidine, due to its pharmacological characteristics and high specificity. Dexmedetomidine is the pharmacologically active D-isomer of medetomidine, which is a highly selective agonist of the α2-adrenoceptor. It is not a pure α2-adrenoceptor agonist, as it is also able to bind to noradrenergic imidazoline receptors [7].

The cardiovascular effects of α2-adrenergic receptor agonists are likely to be one of the greatest concerns. By activating α-adrenergic receptors, these drugs cause significant vasoconstriction, increasing systemic vascular resistance and inducing reflex bradycardia [8]. Even lower doses of dexmedetomidine alone (5 μg.kg−1) were reported to cause a decrease in cardiac output (CO) [9].

Midazolam, belonging to the benzodiazepine class, acts by enhancing the activity of the neurotransmitter GABA, the main inhibitory neurotransmitter of the central nervous system (CNS). The inclusion of this drug in the sedation protocol increases the sedative effect and provides greater intensity of muscle relaxation, with minimal interference in the cardiovascular system, when administered to dogs and cats [10].

The use of opioids, in therapeutic doses, interferes minimally with the cardiorespiratory system, although a decrease in heart rate can be noticed in some animals due to its parasympathomimetic effect [11]. According to the American Association of Feline Practitioners (AAFP) in 2018 [12], opioids are favorable in cats when used as pre-anesthetic medication, they promote analgesia, potentiate sedation and consequently reduce handling stress.

The association of different drugs during a sedative procedure is called neuroleptanalgesia and its greater advantage is the possibility of using combinations of lower dosages and in that way having less side effects and a safer protocol [13].

The study and development of safe protocols, with quick duration and with the possibility of reversion, is necessary within this species, whose management involves significant stress and the need for restraint.

2. Objectives

The aim of the study was to compare the clinical effects such as heart rate, respiratory rate, blood pressure, pulse oximetry, and temperature. The echocardiographic changes, blood gas effects, and the quality of sedation were also compared. The protocols of sedation were dexmedetomidine and methadone associated or not with midazolam. These parameters indicate whether the protocols are safe and effective in causing effective chemical restraint in the feline.

3. Materials and Methods

3.1. Animals. Eighteen animals of the cat’s species, healthy, male, Brazilian shorthair, aged between one to five years, with an average weight of 4.06 ± 0.48 kg. The animals evaluated were considered healthy and selected for the project after presenting results within normal values for the feline species in the clinical, laboratory (blood count, serum biochemistry, renal function), and echocardiographic (performed one week before the study, in case of a normal exam the measurements were considered as baseline). Animals were randomly divided into two groups, each one containing nine cats. The research project was approved by the Ethics Committee in the Use of Animals (CEUA) of the Federal University of Minas Gerais (Protocol no: 383/2017) and written informed consent was obtained from all owners upon admission of study cats to the hospital.

3.2. Animals Preparation. The experiment phase was carried out at the Veterinary Hospital of the Federal University of Minas Gerais. Food fasting of 12 hours and water fasting of 2 hours on the day of preparation and sedation was recommended.

General anesthesia was induced with isoflurane diluted in 100% oxygen, with the aid of a mask coupled to the circuit without partial gas reintroduction. The anesthetic plan was kept superficial, through the observation of clinical parameters, such as maintenance of protective reflexes and cardiorespiratory stability. A 22 G [1] catheter was aseptically introduced into the metatarsal artery to measure invasive blood pressure and to collect 0.5 mL of blood in a syringe with sodium heparin for blood gas analysis (pH, HCO3− (std), base deficit BE(ECF), PaCO2, SaO2, PaO2, sodium, potassium, chlorine, glucose, Hb, Ht, and lactate). The arterial catheter was filled with heparinized saline solution (0.9% NaCl with 5U/mL of sodium heparin) to prevent it from clotting until the experimental protocol was carried out. After implantation of the arterial catheter, the supply of inhaled anesthetic was interrupted, and the animals were housed in individual metal cages 90 × 90 × 40 cm, in an air room, with an average temperature of 25°C, until they recovered from the inhalation anesthesia. A minimum time of 60 minutes was followed between the animals’ recovery and the administration of the drugs to be tested.

After administration of the sedation protocol and latency (the animal showed evident clinical sedation), the animal was positioned on the echocardiography table in the left lateral recumbence and disposable electrode adhesives for ECG were glued to the pads of both thoracic and left pelvic limbs for evaluating the electrocardiographic tracing and obtaining the heart rate. The arterial catheter was connected to a pressure transducer [2] positioned at the level of the heart to obtain systolic, mean, and diastolic blood pressure (SBP, MAP, and DBP). The pulse oximeter sensor was placed on the digit of one of the pelvic limbs to monitor peripheral oxygen saturation (SpO2), all connected to the multiparameter monitor [3]. The respiratory rate, in mov/min, was obtained by observing the movement of the rib cage per minute. Rectal temperature was measured using a digital clinical thermometer.

After shaving the left and right parasternal region, the echocardiographic evaluations were performed by an experienced examiner using the equipment with an electronic sectorial scan transducer (8.0–3.0 MHz) and with electrocardiographic monitoring on the equipment monitor [4].
The echocardiographic examination was performed using two-dimensional mode, M mode, pulsed Doppler (PW), color Doppler, and tissue Doppler, as recommended by the Echocardiography Committee of the Specialty of Cardiology-American College of Veterinary Internal Medicine [14] with modifications suggested by Boon. A. J. [15].

In the bidimensional mode measured, the diameter of the aorta (Ao) in the right parasternal cross section at the level of the heart base [16]. In the same section (M mode), at the level of the tendinous strands, the internal diameters of the left ventricle end-diastolic (LVIDd) and end-systolic (LVIDs) were measured and used to calculate the fractional shortening (FS%) using the formula FS% = [(LVIDd - LVIDs)/LVIDd] x 100 (LOMBARD, 1984) and the ejection fraction in M mode (EF%). The end-systolic and diastolic volumes (VSF and VDF, in mL) were calculated, using the Teichholz method, using the formulas VSF = [7/ (2.4 + LVIDs)(LVIDs + LVIDd)] and VDF = [7/(2, 4 + LVIDd)(LVIDd - LVIDd)] [3], with LVIDd and LVIDs in cm. Afterward, the stroke volume (SV, in mL) and cardiac output (CO, in L/min) were calculated using the formulas SV = EDV - ESV, and CO = SV x FC. Ejection fraction (EF) was also evaluated by the Simpson method, inteventricular septum thickness in diastole (IVSd) and in systole (IVSS), the posterior wall of the left ventricle in diastole (LVPWD) and in systole (LVPWS).

In the four-chamber apical view, the transmital and trans tricuspid flow were acquired and the maximum velocity peaks of the E wave (early ventricular filling), and of the A wave (late ventricular filling) were measured and the E/A wave ratio was calculated. The isovolumic relaxation time (IVRT) was obtained in the apical five-chamber view through an intermediate flow between the mitral inflow and the aortic flow [17]. Pulsed tissue Doppler was used to acquiring velocity waves derived from myocardial motion, with Em (rapid ventricular filling) and Am (late ventricular filling) obtained by apical four-chamber view, with the sample volume positioned on the free wall of the left ventricle in the mitral (parietal) annulus. The relationships between transmitral flow E wave and peak tissue velocity parietal Em (E/Em) and parietal Em/Am were calculated [17]. The peak pulmonary artery flow (P) and the right (TD) and left (TD-I) tissue Doppler were also evaluated.

Assessments of the quality of sedation, muscle relaxation, and posture were performed by an evaluator, who was unaware of the treatment used, assigning scores for the quality of sedation, degree of muscle relaxation, and posture scores, as described in Table 1.

Latency time, in minutes, was established as the time from drug administration until visible sedation was observed or 10 minutes after drug administration. The duration of sedation, in minutes, was established as from the beginning of latency to the beginning of spontaneous movement of the animals (considering the lifting of the head and movement of the limbs). And the time for full recovery, in minutes, was defined as the time between the end of sedation (considering lifting the head and moving the limbs) until the spontaneous movement of the animals and ambulation occurred.

3.3. Experimental Protocol. After acclimatization at the site of the echocardiographic evaluation, the baseline variables (BL) were collected: cardiorespiratory parameters (HR, f, SBP, MAP, DBP, SpO2), T°C, arterial blood gas analysis and sedation, muscle relaxation and nociception scores. Then, the following sedation protocols were administered, randomly by drawing, by the intramuscular route in a single syringe: dexmedetomidine [5] (5 µg.kg−1), midazolam [6] (0.3 mg.kg−1), midazolam [7] (0.3 mg.kg−1) (DMTM, n = 9), or dexmedetomidine (7.5µg.kg−1) and midazolam [6] (0.3 mg.kg−1) (DME, n = 9).

Five minutes after drug latency (time between administration and presentation of evident clinical sedation or 10 minutes after drug administration), cardiorespiratory parameters and T°C (T5) were evaluated again by the same evaluator, and every 5 minutes until completed 10 minutes after latency (T5 and T10, respectively). Sedation, muscle relaxation, and nociception scores were performed again 5 minutes after drug latency time. Arterial blood gas analysis was repeated at T10 (10 minutes after latency) and echocardiographic evaluation was performed at T15 (15 minutes after latency).

3.4. Statistical Analysis. To evaluate the effect of anesthetic protocol, time, and the interaction between these factors on the variables studied, a mixed model was adjusted considering the protocol and time as fixed effects and animals as a random effects in order to account for repeated measurements of the same individual. The means of the groups were compared using the Tukey test. To evaluate the variables that did not assume the assumptions of the analysis of variance, such as sedation, analgesia, and muscle relaxation scores, as well as recovery time, the Wilcoxon test was used to compare the times and the Mann–Whitney test to compare groups. The analyses were performed using the R 3.6.1 software (R Core Team, 2020). A significant difference was considered when p ≤ 0.05. To describe the association between methods for obtaining stroke volumes (systolic volume) and cardiac output, Spearman’s correlation was used using the GraphPad Prism® computer program for Mac OSX Version 8.2.1.

4. Results

There was no difference between the protocols regarding the latency time and the animals’ sedation time. The total recovery time was longer in the animals in the group that received midazolam (DMTM) compared to the DMT group. The mean and standard deviation of latency, sedation, and recovery times (in minutes) are shown in Table 2.

The clinical parameters evaluated (HR, SBP, DBP, MAP, SpO2, f, and T°C) did not differ between the studied protocols at any of the evaluated moments (BL, T5, and T10) (Figure 1; Figure 2). Heart rate decreased significantly at T5 and T10 when compared to baseline in both groups, with a maximum reduction of 46% and 53% at T10 for DMT and DMTM, respectively, but with no difference between T5 and T10 moments (Figure 1). There was no significant increase in systolic, diastolic, and mean blood pressure after the
administration of sedative protocols in both groups (Figure 2). There was a reduction in peripheral hemoglobin oxygen saturation only in the DMT group at time T5 when compared to baseline. The respiratory rate decreased significantly in the DMTM group at T5 and T10 compared to baseline. There was no significant difference in the body temperature of the animals in both groups, in the evaluated moments (Figure 2).
There was no difference in the time, in minutes, to perform the echocardiogram between the two groups (14.31 ± 5.66 and 11.6 ± 2.85 minutes for the DMT and DMTM groups, respectively). There was no difference between the two protocols in any of the echocardiographic parameters evaluated.

Heart rate at T15 was lower compared to baseline values (56% and 51% reduction in the DMT and DMTM groups, respectively). There was a significant reduction in Simpson-mode ejection fraction (8.5% and 14%, in the DMT and DMT group, respectively), as well as in the M-mode ejection fraction (21% and 18%, in the DMT and DMTM group, respectively), in both groups, 15 minutes after the pharmacological latency of the sedation protocols. The measurement of the interventricular septum in systole (IVS) decreased only in the DMTM group. The measurement of left ventricular internal diameter at systole (LVIDs) increased significantly, on average 31%, in both groups. The shortening fraction reduced, on average, 30% and 28% in the DMT and DMTM groups, respectively. There was a 44% and
51% reduction in heart rate values in the DMT and DMTM groups after 15 minutes of pharmacological latency, compared to baseline values. The end-systolic volume (ESV) value increased significantly at T15 in both groups. Stroke volume differed in the TMD group, showing a reduction in this parameter at time T15 compared to baseline. Pulmonary artery flow velocity (P) decreased significantly at time T15 in both groups. A 27% increase in IVRT was observed only in the DMT group after 15 minutes of pharmacological latency. In the right tissue Doppler there was a significant increase of 45% in the DMT group after 15 minutes of sedation. There was a decrease in E (Mit E) and A (Mit A) waves of the mitral valve in the DMTM group. The other echocardiographic parameters, such as IVSd, LVIDd, LVPWD, LVPWS, EDV, Ao, Mit E/A, Tric E/A, and TD-1 showed no difference either in comparison between treatments or in relation to the baseline value (Figures 3–6).

The comparison between the values obtained for stroke volume and cardiac output using the Teichholz and Simpson methods is shown in Figure 7. Both the stroke volume and the cardiac output were higher by the Teichholz method compared to the Simpson method (that is, a tendency to overestimate the data by Teichholz when compared to Simpson). Through the analysis of the Spearman correlation test, there was a weak association between the ejected volume measurements in both the methods ($r = 0.27$), however, the CO values showed a strong association ($r = 0.82$) (Figure 8).

Blood gas parameters did not differ between protocols (Figure 9). There was a decrease in pH at T10 compared to baseline in both groups. Arterial carbon dioxide pressure (PaCO2) increased after 10 minutes of drug latency in both protocols. There was a reduction in arterial oxygen pressure (PaO2), arterial oxygen saturation (SaO2), and hemoglobin (Hb) in both groups at T10. Arterial sodium concentration (Na+) was reduced only in the DMT group. Arterial chloride (Cl–) concentration decreased in both groups, with a significant difference compared to baseline. There was a reduction in lactate when compared to baseline values in both protocols at the time evaluated (T10). There was no
5. Discussion

Our main goal was to establish a sedation protocol for felines that promotes adequate chemical restraint with minimal alterations in echocardiographic, blood gas, and clinical parameters.

In this study, sedation was effective for both protocols, but with important changes in cardiorespiratory and echocardiographic parameters, such as bradycardia, moderate hypoxemia, reduced cardiac output, and systolic function. In addition, the results of this research suggest that there were no differences in the thickness of the diastolic diameter of the ventricular free wall and the interventricular septum, thus not affecting the diagnosis of hypertrophic cardiomyopathy in felines.

Comparing the mean baseline parameters, such as HR, f, SBP, DBP, and MBP, with other studies that evaluated these same baseline parameters in felines [18–20], no difference in the parameter’s bicarbonate (HCO3−), excess of bases (BE), potassium concentration (K+), and anion gap (Figure 10).

Sedation, nociceptive response, and muscle relaxation scores did not differ between protocols. After 5 minutes of drug latency, both groups obtained sedation, nociception, and myorelaxation scores compatible with deep sedation (Figure 11).

**Figure 3:** Values for interventricular septum in diastole (IVSd) and systole (IVSs), left ventricular posterior wall in diastole (LVPWD), and systole (LVPWS) and left ventricular internal diameter in diastole (LVIDd) and systole (LVIDs), in 18 sedated cats with the combination of dexmedetomidine (7.5ug/kg) and methadone (0.3 mg/kg) (DMT, n = 9) or dexmedetomidine (5ug/kg), methadone (0.3 mg/kg), and midazolam (0.3 mg/kg) (DMTM, n = 9), both by the intramuscular route. Values are presented as mean ± standard deviation. a, b: different lowercase letters indicate a significant difference between moments within the same group according to the Tukey test (p < 0.05).

**Figure 4:** Values for shortening fraction (FS%), ejection fraction by Simpson (FE), heart rate (HR), end-systolic volume (ESV), ejection volume by Simpson (VE), and cardiac output by Simpson (CO), in 18 cats sedated with the association of dexmedetomidine (7.5 ug/kg) and methadone (0.3 mg/kg) (DMT, n = 9) or dexmedetomidine (5 ug/kg), methadone (0.3 mg/kg), and midazolam (0.3 mg/KG) (DMTM, n = 9), both by the intramuscular route. Values are presented as mean ± standard deviation. a, b: Different lowercase letters indicate a significant difference between moments within the same group according to the Tukey test (p < 0.05).
Values of E wave (E) and A wave (A) in the mitral valve, ratio of the E/A wave in the mitral (Mit E/A), E wave (tricus (E)), and A wave (tricus (A)) in the tricuspid valve, and tricuspid E/A wave ratio (tric E/A) in 18 cats sedated with the combination of dexmedetomidine (7.5 ug/kg) and methadone (0.3 mg/kg) (DMT, n = 9) or dexmedetomidine (5 ug/kg), methadone (0.3 mg/kg), and midazolam (0.3 mg/kg) (DMM, n = 9), both by intramuscular route. Values are presented as mean± standard deviation. a, b: different lowercase letters indicate a significant difference between moments within the same group according to the Tukey test (p < 0.05).

Figure 5: Values of E wave (E) and A wave (A) in the mitral valve, ratio of the E/A wave in the mitral (Mit E/A), E wave (tricus (E)), and A wave (tricus (A)) in the tricuspid valve, and tricuspid E/A wave ratio (tric E/A) in 18 cats sedated with the combination of dexmedetomidine (7.5 ug/kg) and methadone (0.3 mg/kg) (DMT, n = 9) or dexmedetomidine (5 ug/kg), methadone (0.3 mg/kg), and midazolam (0.3 mg/kg) (DMM, n = 9), both by intramuscular route. Values are presented as mean± standard deviation. a, b: different lowercase letters indicate a significant difference between moments within the same group according to the Tukey test (p < 0.05).

Several reports using dexmedetomidine alone or in combination with other drugs showed divergent results regarding the effect on blood pressure in cats [13, 26, 27]. These discrepancies in the results of the studies can be explained by the use of different doses, the measurement time of this parameter, as well as the drug combinations that differ between the articles. In addition, the different methods of measuring blood pressure and stress levels in cats across studies may also affect the results [19, 28]. In the present project, a 50% higher dose of dexmedetomidine in the DMT group did not result in higher SBP, DBP, and MBP values compared to DMM, suggesting that hypertension, at the doses used, does not occur in a dose-dependent manner.

Low values of SpO2, f, PaO2, and SaO2 and high values of PaCO2 were observed indicating moderate hypoxemia and respiratory depression [29]. Leppänen [30] reported that higher doses of dexmedetomidine, as well as other α2-adrenergic agonists, cause a dark red or pale color on the tongue, due to peripheral vasoconstriction, which consequently can cause difficulty in reading the oximeter due to the reduction in peripheral perfusion. Thus, positioning the pulse oximeter on the tongue in animals sedated with these drugs will result in borderline values or severe hypoxemia. In this project, the oximeter was positioned on the digit, which could also cause reading difficulties due to peripheral vasoconstriction. Another factor that the research by Leppänen [30] cited that may explain the drop-in oximetry in patients is respiratory depression caused by sedation with the use of α2-agonist.

The occurrence of respiratory depression is mainly observed by the reduction of respiratory movements, resulting in an increase in PaCO2, induced by the action of the drug in the upper respiratory centers due to the distribution of α2 adrenergic receptors in the brain [31, 32]. In addition, Flores et al [33] suggest that midazolam may reduce the ventilatory response, leading to increased PaCO2 and central respiratory depression. Therefore, this probable synergistic or additive depressant effect on the respiratory center could explain the significant reduction in the respiratory rate in animals that received midazolam (DMM).

There was no significant change in rectal temperature in any of the protocols used over time evaluated. In the article by Selmi et al. [13], the rectal temperature of cats decreased significantly compared to baseline after 40
minutes of sedation. The short evaluation time of the research project may have been a limitation for not having observed changes in the animal’s rectal temperature.

Regarding sedation, nociceptive response, and muscle relaxation scores according to the simple descriptive analysis table (adapted from Ansah et al., [34]), there was no difference between the protocols. Both protocols achieved a satisfactory degree of sedation, muscle relaxation, and analgesia. According to the article by Selmi et al. [13], the combination of an α2-agonist with an opioid in cats resulted in a greater degree of sedation compared to the use of an α2-agonist alone.

Ansah et al., [34] concluded that the use of dexmedetomidine in cats at doses (25, 50, and 75 μg/kg) induces, in a dose-dependent manner, sedation, analgesia, and clinically important muscle relaxation. An article comparing the use of dexmedetomidine alone or in combination with various opioids in healthy dogs reported that the sedative effects of dexmedetomidine were more pronounced when combined with a variety of opioids, particularly with butorphanol, meperidine, and methadone, compared with the sedative effects when dexmedetomidine was administered alone [35]. These studies justify the excellent degree of sedation that the present research obtained in both protocols, noting that the association of dexmedetomidine with opioids, such as methadone, associated or not with midazolam potentiates the sedative degree, allowing the use of low doses of drugs.

According to our research, the group that received midazolam did not obtain more intense muscle relaxation scores than the other group, as predicted in the literature. This fact may have occurred due to a limitation of the muscle relaxation scale used, which ranges from 0 (not relaxed) to 2 (very well relaxed), that is, 3 possible classifications. However, if we to analyze the individual values, 100% of the
DMTM group had a maximum score, compared to 67% of the DMT group, indicating a probable better muscle relaxation when using midazolam associated with dexmedetomidine and methadone.

In the blood gas analysis, there was no difference between the groups. A significant drop was observed in both groups, compared to baseline values, for pH, PaO2, SaO2, Hb, Cl, and lactate. The respiratory depression caused by the drugs used in both protocols explains the increase in PaCO2, and consequently the fall in pH, due to the increase in carbonic acid caused by respiratory acidosis [36].

In the present study, lactate values remained within the normal range for the species, 0.5 to 2.0 mmol/L [37], both at BL and T10 times, in both groups. Hyperlactatemia occurs when lactate production exceeds metabolism and its elimination, especially in situations of activation of the hypothalamic-pituitary-adrenal axis with consequent vasoconstriction and tissue hypoxia. However, there was a significant reduction in lactate after 10 minutes of pharmacological latency (T10) compared to baseline in both groups. Biermann et al. [38] justified this observation by the fact that sedation provides muscle

---

**Figure 7:** Values of stroke volume (ejected volume) and cardiac output (CO), obtained by the Simpson and Teichholz methods, in 18 cats sedated with the association of dexmedetomidine (7.5 μg/kg) and methadone (0.3 mg/kg) (DMT, n = 9) or dexmedetomidine (5 μg/kg), methadone (0.3 mg/kg), and midazolam (0.3 mg/kg) (DMTM, n = 9), both by the intramuscular route. Values are presented as mean± standard deviation.

---

**Figure 8:** (a) Spearman correlation between the ejected volume obtained by the Teichholz and Simpson methods. The correlation obtained had \( r = 0.27 \) of 18 measurements. (b) Spearman correlation between cardiac output (CO) obtained by the methods of Teichholz and Simpson. The correlation obtained had \( r = 0.82 \) out of 18 measurements.
relaxation and stress reduction, decreasing lactate concentrations.

There was a decrease in Hb concentration after sedation with both protocols. The reduction of red blood cells and total hemoglobin concentration was also observed in the study by Biermann et al. [38]. In conscious animals, catecholamines respond to stress through splenic contraction leading to an increase in hemoglobin. This spleen response is minimized with the use of sedative drugs or associations with properties that reduce sympathetic activity, such as alpha-2-agonists, inducing a reduction in Hb values [39].

In contrast, the report by Congdon et al. [40], which evaluated the use of dexmedetomidine (10μg/kg) alone in dogs, did not observe a reduction in hemoglobin concentration after sedation with this drug.

Na+ decreases significantly in the DMT group at time T5. Cl-reduced significantly in both groups but remained within the normal range for the species. Reductions in these electrolytes have not been observed with the use of dexmedetomidine alone in dogs [40]. As in the publication by Volpato et al. [41], who also did not observe changes in chloride after sedation of felines, using the protocols dexmedetomidine (5μg/kg) + butorphanol (0.3 mg/kg) and dexmedetomidine (5μg/kg) + butorphanol (0.3 mg/kg) + ketamine (3 mg/kg). There was no significant
difference in the other electrolyte values obtained through blood gas analysis in this study.

In the present study, the animals were selected after verifying that they did not have any heart disease. In addition, they also did not show signs of thromboembolism, such as left atrial dilatation (LA longitudinal diameter < 1.5 cm) and the presence of spontaneous contrast within the atrial chambers.

Postsedation echocardiographic variables with DMT and DMTM were compared with presedation values and between protocols, in healthy cats. There was an increase in ventricular diameters, and a reduction in stroke volume and...
cardiac output. The other echocardiographic parameters, such as IVDd, LIVDd, LPWd, LPWs, EDV, Ao, Mit E/A, tric E/A, and TD-I showed no difference either in comparison between treatments or in relation to the baseline.

In this research, both the ejection fraction and the shortening fraction reduced in relation to baseline, with significance, but there was no difference between the protocols. The FS% and EF% are indexes that quantitatively assess the left ventricular systolic function and demonstrate myocardial contractility, which is easily altered due to changes in HR, pre and postload, and contractility [15, 42]. Among these variables, HR has the least influence on systolic function.

The FS% is a percentage change in the dimension of the left ventricular cavity that occurs in systole [15]. In most cats, the FS% is 35 to 65%, although there is variability [43]. A low FS% value may be secondary to a decrease in preload, an increase in afterload, or a decrease in contractility. At work, there was no change in preload because the end-diastolic volume did not change, the increase in afterload may have influenced more significantly low values of FS% and a decrease in cardiac output.

The end-systolic volume is determined by cardiac contractility, by the blood volume that remains in the LV and the stroke volume corresponds to the amount of blood that leaves the heart, constituting a more accurate way to assess myocardial contractility in the presence of mitral regurgitation [43]. In this study, there was a limitation in the calculation of systolic and end-diastolic volumes using the Simpson method due to poor contact between the device and the HR electrodes, making the value and calculation by this method unavailable to the software.

The α2 agonists promote a sympatholytic effect, with depression of the vasomotor center, an increase in vagal tone and baroreceptor activity [44], thus, a reduction in myocardial contractility is observed. In the present study, there was an increase in end-systolic volume (ESV) in both groups, which may suggest that the dose and the drug combinations used in this study negatively interfered with myocardial contractility and did not interfere with the increase in afterload, as in our work the PAS did not change. In the article by Biermann et al. [45], a similar increase in FSV was observed after sedation of cats in protocols in which dexmedetomidine (5 μg/kg) was inserted. The authors also justified this result in view of the particularities of alpha-2-adrenergic agonists in reducing heart contractility or increasing afterload through the vasoconstriction that these drugs cause. The increase in the end-systolic volume results in a decrease in the stroke volume, which together with the decrease in heart rate caused by alpha-2-agonists, corroborates the decrease in cardiac output [23].

Cardiac output is the result of heart rate multiplied by stroke volume (stroke volume), Kitahara et al. [46] reported a reduction in bradycardia-related CO and CI and an increase in peripheral vascular resistance attributed to the direct vasoconstriction effects of α2-adrenergic agonists. In the study by Biermann et al. (2012) [45], the combinations of dexmedetomidine (5 μg/kg) + midazolam (0.4 mg/kg) + butorphanol (0.4 mg/kg) and dexmedetomidine (5 μg/kg) + ketamine (3 mg/kg), reduced cardiac output by 54% and 53%, respectively. Corroborating these results, the current research reveals a significant reduction in this variable in both groups at T15, with no difference between the protocols. In the DMT group, the CO was reduced by 53%, while in the DMTM group by 56% in relation to baseline measurements, with no difference between the groups.

A human study that evaluated the agreement between LV stroke volume measurements, obtained by three-dimensional color mapping, three-dimensional volumetric variation, Teichholz’s formula, modified Simpson’s method, and Doppler estimation, observed that there was a significant linear correlation between the measurements of stroke volume by three-dimensional color mapping and measured by Doppler (r = 0.83), Simpson’s rule (r = 0.87) and three-dimensional volumetric variation (r = 0.93), with P < 0.01 for all. On the other hand, there was no significant correlation with the Teichholz method (r = 0.30, P = 0.3) [47]. In the present study, the correlation of the volume ejected by the Teichholz and Simpson methods was also low (r = 0.27). However, the CO obtained by the two methods showed a strong correlation (r = 0.82). Biermann, et al. [45] evaluated the agreement and repeatability of four echocardiography methods to measure stroke volume and cardiac output in cats and observed that the Teichholz and Trace (flow) methods were acceptable and repeatable, suggesting that these provide more representative values, so they could be the most useful methods for measuring stroke volume and cardiac output in cats.

Stroke volume was not different between the protocols, however, in the DMTM group, stroke volume by the Simpson method was significantly reduced, which did not happen with the TeichHolz method. However, the percentage reduction in stroke volume in the DMTM group was similar between the methods, being 12% and 11.4% in the Teichholz and Simpson methods, respectively. The fact that the mean and standard deviation were lower in the Simpson method both at baseline (2.54 ± 0.51) and at T15 (2.25 ± 0.50), compared to Teichholz (4.73 ± 1.48) and (4.12 ± 1.05), baseline and T15, respectively, may have contributed to a significant reduction in stroke volume in the DMTM group, although clinically the percentage reduction between the methods was similar. As the stroke volume reduction observed was not intense, this may suggest that the CO reduction was mainly influenced by contractility and by the reduction in heart rate.

LV diastolic function comprises the chamber’s ability to accommodate adequate blood volume to maintain cardiac output and meet metabolic demand. Tissue Doppler is an echocardiographic method associated with the assessment of left and right ventricular diastolic function to obtain the relationship between the E’ and A’ (E’/A’) wave velocities that are measured both in the left ventricular free wall, at the level of the mitral valve insertion, and in the right ventricular free wall, at the level of the tricuspid valve insertion. This relationship makes it possible to demonstrate changes in the speed of movement of the heart muscle [48, 49]. Variations of these indexes beyond the
limit of normalcy point to diastolic dysfunction and, depending on the pattern of abnormality, it can be inferred that the individual has impaired ventricular relaxation, that is, the active phase of diastole, or that he or she has less ventricular compliance/distensibility, in other words, of the passive phase of diastole [50]. Tissue Doppler ratio values (TD-I and TD-r) when <1 indicate diastolic dysfunction, which in this research did not happen after the administration of the protocols, therefore, there was no impairment of diastolic function with the drugs and doses that were used in both protocols.

By positioning the sample volume between the septal leaflet of the mitral valve and the left ventricular outflow tract, the transmitral and aortic flows are simultaneously recorded, which allows obtaining the isovolumic relaxation time (IVRT) [15, 51]. In the present study, the significant increase of 27% in IVRT may have been influenced by the reduction in heart rate after sedation. Faster myocardial relaxation results in lower IVRT values, and prolonged relaxation leads to an increase in this parameter (Schober and Todd) [17]. According to Nishimura et al. [52], the higher the heart rate, the lower the IVRT value, as tachycardia and sympathetic stimulation can exacerbate isovolumic relaxation, reducing diastolic filling time and accelerating early diastolic elastic recoil of the left ventricle, the opposite happens when the heart rate drops significantly. This index is also influenced by volume overload conditions, leading to an increase in the isovolumic relaxation time [53].

6. Conclusions

The protocols evaluated in this research were safe, well-tolerated by the animals, and demonstrated similar sedation scores and clinical, blood gas, and echocardiographic parameters. They provided appropriate levels of sedation, analgesia, and muscle relaxation but also induced cardiorespiratory depression with a significant reduction in the cardiac output. Considering healthy young cats, the protocols can be recommended. However, more studies are needed for disease animals, especially those with cardiomyopathies.

Data Availability

Access to data is restricted. The link for the statement can be found at "https://journals.sagepub.com/doi/10.1177/1098612X17720327?url_ver=Z39.88-2003-...................-amp;rfr_id=ori%3Arid%3Acr_pub++0pubmed...................-amp;rfr_dat=cr_pub++0pubmed...................-amp;" and "https://avmajournals.avma.org/view/journals/javma/222/1/javma.2003.222.37.xml"

Ethical Approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. This study was approved by the Ethical Committee for Animal Use (CEUA-UFMG) under protocol number 383/2017.

Consent

The written consent form was obtained from the owners or legal guardians of all animals described in this work.

Conflicts of Interest

The authors declare that there are no conflicts of interest related to this research, authors, and/or publishing.

Acknowledgments

The authors would like to express their gratitude to Fundação de Ensino, Pesquisa e Extensão–FEPE for its support of the publication of this article. The authors acknowledge Zoetis, who trusted the achievement of this research and contributed by providing the drug dexmedetomidine. The authors acknowledge the Institutional Repository of the Federal University of Minas Gerais for posting (https://repositorio.ufmg.br/bitstream/1843/35650/1/Dissertacao%20Bruna.pdf).

References

[1] M. Martin-Flores, D. M. Sakai, R. M. Muto et al., “A flexible endotracheal tube introducer improves first-attempt success of intubation in cats by novice anesthetists,” Journal of the American Veterinary Medical Association, vol. 260, no. 11, 2022.

[2] A. De Jong, A. Rolle, J. Pensier, M. Capdevila, and S. Jaber, “First-attempt success is associated with fewer complications related to intubation in the intensive care unit,” Intensive Care Medicine, vol. 46, 2020.

[3] G. H. Julião and C. J. X. Abimussi, Uso de dexmedetomidina em Medicina Veterinária: revisão de literatura, Rev Educ Contín Med Veterinária e Zootec do CRMV-SP, vol. 17, iss. 1, pp. 26–32, 2019.

[4] M. Clausse, P. Nejamkin, C. A. Bulant et al., “A low-cost portable simulator of a domestic cat larynx for teaching endotracheal intubation,” Veterinary Anaesthesia and Analgesia, vol. 47, pp. 676–680, 2020.

[5] B. T. Simon and P. V. Steagall, “Feline procedural sedation and analgesia: when, why and how,” Journal of Feline Medicine Surgery, vol. 22, no. 11, 2020.

[6] D. C. Brodbelt, K. J. Blasiss, R. A. Hammond et al., “The risk of death: the confidential enquiry into perioperative small animal fatalities,” Veterinary Anaesthesia and Analgesia, vol. 35, no. 5, pp. 365–373, 2008.

[7] J. P. Hieble and R. R. Ruffolo Jr, “Possible structural and functional relationships between imidazoline receptors and alpha 2-adrenoceptors,” Annals of the New York Academy of Sciences, vol. 763, pp. 8–21, 1995.

[8] R. S. Sinatra, J. S. Jahr, and J. M. Watkins-Pitchford, The Essence of Analgesia and Analgesics, Cambridge Medicine, New York, 2011.

[9] E. R. Carvalho, T. Champion, F. Ambrosini, G. A. da Silva, G. C. Freitas, and R. G. D’Otaviano de Castro Vilani, “Dexmedetomidine low dose followed by constant rate infusion and antagonism by atipamezole in isoflurane-anesthetized cats: an echocardiographic study,” Veterinary Anaesthesia and Analgesia, vol. 46, no. 1, pp. 43–54, 2019.

[10] A. Lagos-Carvajal, P. Queiroz-Williams, A. da Cunha, and C. C. Liu, “Determination of midazolam dose for co-
induction with alfaxalone in sedated cats," *Veterinary Anesthesia and Analgesia*, vol. 46, no. 3, pp. 299–307, 2019.

[11] K. A. Grimm, W. J. Tranquilli, D. R. Gross et al., "Cardio-pulmonary effects of fentanyl in conscious dogs and dogs sedated with a continuous rate infusion of medetomidine," *American Journal of Veterinary Research*, vol. 66, no. 7, 2005.

[12] S. A. Robertson, S. M. Gogolinski, P. Pascoe, H. L. Shafford, J. Sager, and G. M. Griffenhagen, "AAFP feline anesthesia guidelines," *Journal of Feline Medicine & Surgery*, vol. 20, no. 7, pp. 602–634, 2018.

[13] A. L. Selmi, G. M. Mendes, B. T. Lins, J. P. Figueiredo, and G. R. Barbudo-Selmi, "Evaluation of the sedative and cardiorespiratory effects of dexmedetomidine, dexmedetomidine-butorphanol, and dexmedetomidine-ketamine in cats," *Journal of the American Veterinary Medical Association*, vol. 222, no. 1, pp. 37–41, 2003.

[14] W. P. Thomas, C. E. Gaber, G. J. Jacobs et al., "Recommendations for standards in transthoracic two-dimensional echocardiography in the dog and cat," *Veterinary Radiology and Ultrasound*, vol. 35, no. 3, pp. 173–178, 1994.

[15] J. A. Boon, *Veterinary Echocardiography*, Blackwell, Hoboken, New Jersey, United States, 2011.

[16] K. Hansson, J. Haggstrom, C. Kvart, and P. Lord, "Left atrial without left atrial enlargement," *Veterinary and Comparative Neurology*, vol. 69, pp. 1521–1528, 2017.

[17] E. J. Schober and A. Todd, "Echocardiographic assessment of left ventricular geometry and the mitral valve apparatus in cats with hypertrophic cardiomyopathy," *Journal of Veterinary Cardiology*, vol. 12, no. 1, pp. 1–16, 2010, Available from:.

[18] V. C. Lemos, J. Q. Sande, V. F. Barbosa, J. M. C. Neto, E. F. M. Filho, and C. H. D. Iwassa, " Avaliação da dexmedetomidina e do tramadol, associados ao midazolam, em gatas anestesiadas com isoflurano e submetidas à ovario-histerectomia," *Arquivo Brasileiro de Medicina Veterinária e Zootecnia*, vol. 69, pp. 1521–1528, 2017.

[19] E. Johard, A. Tidholm, I. Lungvall, J. Haggström, and K. Höglund, "Effects of sedation with dexmedetomidine and buprenorphine on echocardiographic variables, blood pressure and heart rate in healthy cats," *Journal of Feline Medicine and Surgery*, vol. 20, no. 6, pp. 554–562, 2018.

[20] J. Cremer and C. H. Ricco, "Cardiovascular, respiratory and sedative effects of intramuscular alfaxalone, butorphanol and dexmedetomidine compared with ketamine, butorphanol and dexmedetomidine in healthy cats," *Journal of Feline Medicine and Surgery*, vol. 20, no. 10, pp. 973–979, 2018.

[21] T. Kanda and Y. Hikasa, "Effects of medetomidine and midazolam alone or in combination on the metabolic and neurohormonal responses in healthy cats," *Canadian Journal of Veterinary Research*, vol. 72, no. 4, pp. 332–339, 2008.

[22] A. Bagatini, C. R. Gomes, M. Z. Masella, G. Rezer, R. A. Bagatini, and R. G. D. Dantas, "Dexmedetomidina: farmacologia e uso clinico," *Revista Brasileira de Anestesiologia*, vol. 52, no. 5, pp. 606–617, 2002.

[23] J. C. Murrell and L. J. Jellebrekers, *Medetomidine and Dexmedetomidine: A Review of Cardiovascular Effects and Antinociceptive Properties in the Dog*, Veterinary Anaesthesia and Analgesia, vol. 32, iss. 3, pp. 117–127, 2005.

[24] E. Kuusela, O. Vainio, A. Kaistinen, S. Kobylin, and M. Raekallio, "Sedative, analgesic, and cardiovascular effects of levomedetomidine alone and in combination with dexmedetomidine in dogs," *American Journal of Veterinary Research*, vol. 62, no. 4, pp. 616–621, 2001.

[25] B. KuKanich and A. J. Wiese, "Opioids," in *Veterinary Anesthesia and Analgesia: The Fifth Edition of Lumb and Jones* Wiley, Hoboken, New Jersey, U.S, 2017.

[26] L. A. Lamont, B. J. Bulmer, K. A. Grimm, W. J. Tranquilli, and D. D. Sisson, "Cardiopulmonary evaluation of the use of medetomidine hydrochloride in cats," *American Journal of Veterinary Research*, vol. 62, no. 11, 2001.

[27] E. R. Menegatti, D. P. Campana, R. L. Parrilha, and L. Z. Furlan, "Evaluation of cardiorespiratory effects of combinations of dexmedetomidine and atropine in cats," *Journal of Feline Medicine and Surgery*, vol. 11, no. 10, pp. 783–792, 2009.

[28] S. Brown, C. Atkins, R. Bagley et al., "Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats," *Journal of Veterinary Internal Medicine*, vol. 21, no. 3, pp. 542–558, 2007.

[29] T. Grubb, J. Sager, J. S. Gaynor, E. Montgomery, J. A. Parker, and H. Shafford, "AAHA anesthesia and monitoring guidelines for dogs and cats, 2020," https://www.aaha.org/aaha-guidelines/2020-aha-anesthesia-and-monitoring-guidelines-for-dogs-and-cats/anesthesia-and-monitoring-home.

[30] M. K. Leppänen, B. C. McKusick, M. M. Granholm, F. C. Westerholm, R. C. McKie, and C. E. Short, "Clinical efficacy and safety of dexmedetomidine and buprenorphine, butorphanol or diazepam for canine hip radiography," *Journal of Small Animal Practice*, vol. 47, no. 11, pp. 663–669, 2006.

[31] R. M. Venn, J. Hell, and R. M. Grounds, "Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care," *Critical Care*, vol. 4, no. 5, pp. 302–308, 2000.

[32] S. Kastner, P. De Weerd, M. A. Pink, M. I. Elizondo, R. Desimone, and L. G. Ungerleider, "Modulation of sensory suppression: implications for receptive field sizes in the human visual cortex," *Journal of Neurophysiology*, vol. 86, no. 3, 2001.

[33] F. N. Flóres, S. Geni Tavares, A. N. de Moraes, and N. Olenskovicz, "Aazerone e sua associação com xilazina ou dexmedetomidina em suínos," Ciência Rural, vol. 39, pp. 1101–1107, 2009.

[34] O. B. Ansah, M. Raekallio, and O. Vainio, "Comparison of three doses of dexmedetomidine with medetomidine in cats following intramuscular administration," *Journal of Veterinary Pharmacology and Therapeutics*, vol. 21, no. 5, pp. 380–387, 1998.

[35] L. T. Nishimura, A. Auckburally, J. Santilli et al., "Effects of dexmedetomidine combined with commonly administered opioids on clinical variables in dogs," *American Journal of Veterinary Research*, vol. 79, no. 3, pp. 267–275, 2018.

[36] B. H. Pypendop, L. S. Barter, S. D. Stanley, and J. E. Ilkiw, "Hemodynamic effects of dexmedetomidine in isoflurane-anesthetized cats," *Veterinary Anesthesia and Analgesia*, vol. 38, no. 6, pp. 555–567, 2011.

[37] R. A. Packer, L. A. Cohn, D. R. Wohlstadter et al., "D-lactic acidosis secondary to excocrine pancreatic insufficiency in a cat," *Journal of Veterinary Internal Medicine*, vol. 19, no. 1, pp. 106–110, 2005.

[38] K. Biermann, S. Hungerbühl, R. Mischke, and S. R. Kästner, "Sedative, cardiovascular, haematologic and biochemical effects of four different drug combinations administered intramuscularly in cats," *Veterinary Anesthesia and Analgesia*, vol. 39, no. 2, pp. 137–150, 2012.

[39] A. Adetunji and O. Osunbunmi, "Haematological effects of azaperone sedation in pigs," *African Journal of Biomedical Research*, vol. 3, 2000.
[40] J. M. Congdon, M. Marquez, S. Niyom, and P. Boscan, “Evaluation of the sedative and cardiovascular effects of intramuscular administration of dexmedetomidine with and without concurrent atropine administration in dogs,” Journal of the American Veterinary Medical Association, vol. 239, no. 1, pp. 81–89, 2011.

[41] J. Volpato, C. R. S. Mattoso, S. L. Beier, M. M. Coelho, R. Tocheto, and M. G. Ceregatti, “Efeitos de dois protocolos de sedação sobre as variáveis bioquímicas em gatos,” Arquivo Brasileiro de Medicina Veterinária e Zootecnia, vol. 68, pp. 1129–1136, 2016.

[42] S. L. Minors and M. R. O’Grady, “Resting and dobutamine stress echocardiographic factors associated with the development of occult dilated cardiomyopathy in healthy Doberman pinscher dogs,” Journal of Veterinary Internal Medicine, vol. 12, no. 5, pp. 369–380, 1998.

[43] R. W. Nelson and C. G. Couto, Medicina interna de pequenos animais, 4 ed. Elsevier, Rio de Janeiro, Brasil, 2010.

[44] H. de S. Spinosa, S. L. Gorniak, and M. M. Bernardi, Farmacologia aplicada à medicina veterinária. 2. ed, Guanabara Koogan, Rio de Janeiro, Brasil, 1999.

[45] K. Biermann, S. Hungerbühler, and S. B. R. Kästner, “Comparison of stroke volume and cardiac output as measured by a single observer using four different ultrasound techniques in six clinically healthy cats,” The Veterinary Journal, vol. 194, no. 3, pp. 433–436, 2012.

[46] F. R. Kitahara, S. R. G. Cortopassi, D. A. Otsuki, T. R. Intelizano, D. T. Fantoni, and J. O. C. Auler Junior, “Efeitos hemodinâmicos da dexmedetomidina em cães,” Revista Brasileira de Ciência Veterinária, vol. 9, pp. 128–130, 2002.

[47] W. Oliveira, A. C. T. Rodrigues, D. Le Bihan, and E. Al, “Avaliação do volume de Ejeção ventricular esquerda pelo ecocardiograma tridimensional colorido,” Rev Bras eco-cardiografa, vol. 24, pp. 44–50, 2011.

[48] S. J. Lester, A. J. Tajik, R. A. Nishimura, J. K. Oh, B. K. Khandheria, and J. B. Seward, “Unlocking the mysteries of diastolic function. Deciphering the rosetta stone 10 Years later,” Journal of the American College of Cardiology, vol. 51, no. 7, pp. 679–689, 2008.

[49] S. M. Bierig and J. Hill, “Echocardiographic evaluation of diastolic function,” Journal of Diagnostic Medical Sonography, vol. 27, iss. 2, pp. 65–78, 2011.

[50] E. C. Soares, M. H. M. A. Larsson, A. G. T. Daniel, M. M. Fantazzini, F. L. Yamaki, and R. C. e Pereira, índices ecodopplercardiográficos de função diastólica de gatos saudáveis não sedados, Ciência Rural, Brazil, 2005.

[51] F. A. Morcerf, R. S. Thevenard, J. Fuks, and A. C. Azevedo, “Medidas ecocardiográficas de referência em amostra da população,” Ecocardiografia. Método e Valores Normais. Arq Bras Cardiol, vol. 21, 1976.

[52] R. A. Nishimura, P. R. Housmans, L. K. Hatle, and A. J. Tajik, “Assessment of diastolic function of the heart: background and current applications of Doppler echocardiography. Part I. Physiologic and pathophysiologic features,” Mayo Clinic Proceedings, vol. 64, no. 1, pp. 71–81, 1989.

[53] J. Fragata and J. C. Areias, Effects of Gradual Volume Loading on Left Ventricular Diastolic Function in Dogs: Implications for the Optimisation of Cardiac Output: Volume Loading and Diastolic Function, Heart, Oxford, Oxfordshire, United Kingdom, 1996.